Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment [Phase 3]

View source ↗

Summary

This Phase 3 trial update reports the completion of a study evaluating the efficacy and safety of Galantamine in patients with Mild Cognitive Impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment
• Dementia

Drugs mentioned

• Galantamine (galantamine)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Dementia, Alzheimer Disease | Phase 3 | Status: COMPLETED